Biotech Values

[DewDiligence]

P/E is a difficult metric to apply at this stage of MNTA’s development, where net income is apt to be ramping steeply and is affected by such transient considerations as the reimbursement of NVS’ development costs and the use of NOL’s to shield MNTA’s net income from taxation.

An alternative approach to valuation is to try to ascertain what MNTA would be worth in a buyout. The table in #msg-54153359 provides many data points to use as comparators.